DCN Diagnostics, Inc. Announces New Chief Operating Officer, Dr. Patrick Vaughan

Share Article

DCN Diagnostics, Inc., the definitive resource for rapid assay system development, insight and expertise, announced today that Dr. Patrick Vaughan has joined the company as Chief Operating Officer (COO).

DCN Diagnostics

www.dcndx.com

Patrick strengthens DCN’s rapidly-growing contract product development & consulting capability…he will be key in continuing to solidify the company’s position as one of the world’s premier rapid diagnostic assay contract development & solutions providers.

Dr. Vaughan will be responsible for overseeing key aspects of day-to-day operations of DCN’s product development, engineering and consulting groups, as well as providing strategic and technical guidance to DCN’s client base in rapid diagnostic assay system development. Dr. Vaughan will also be heavily involved in new market and technology evaluation for the company.

Dr. Vaughan joins DCN following his tenure as Vice President of R&D at Trinity Biotech plc, a NASDAQ traded IVD company, where he spearheaded their R&D efforts in both reagent/device and instrument development for over a decade both in Europe and USA. In addition to product development, he successfully transferred multiple products from R&D to manufacturing and oversaw the technical transfer of multiple company and product portfolio acquisitions.

Dr. Vaughan brings a wealth of knowledge and in-depth experience in taking development projects from concept through to successful product launch. Having steered products through to FDA 510K approval and CE marking, he brings invaluable experience in dealing with FDA and other regulatory authorities. He will complement and bolster DCN’s capability in total system development, clinical trials and commercialization.

Dr. Brendan O’Farrell, President of DCN said, “Patrick strengthens DCN’s rapidly-growing contract product development and consulting capability, bringing his years of IVD industry experience in managing all stages of product development, validation, transfer, clinical trials and regulatory approvals. He will additionally be instrumental in evaluating, developing and executing company strategy in new markets and new technologies. We expect that he will be key in continuing to solidify the company’s position as one of the world’s premier rapid diagnostic assay contract development and solutions providers.”

Said Dr. Vaughan, "I am thrilled to be part of the DCN team. The bulk of my career has been spent in the diagnostic technology industry and I look forward to providing the benefit of that experience to the DCN team and to their growing client base in rapid assay applications, from medical diagnostics to veterinary, bio-defense, food science, agricultural and other market segments.”

About DCN Diagnostics, Inc.
DCN Diagnostics is the definitive resource for rapid assay system development insight and expertise. Headquartered in Carlsbad, CA, DCN Diagnostics assists clients through all stages of new product design and development to create user-centric, high performance rapid assay systems. DCN Diagnostics combines a deep understanding of lateral flow assay applications, markets and technology with advanced design and development capabilities to bring products to market.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Margaret Cogan
DCN Diagnostics
+1 (760) 804-3886
Email >
@DCNDiagnostics
since: 07/2015
Follow >
DCN Diagnostics

Visit website